SERVICES

Below is a modular representation of the research services we offer. Each subsequent module incorporates our analysis from the previous module(s). Make a selection from one of the four options (1, 2, 3, or 4 modules) presented below.

DATA ANALYSIS
Evaluate clinical data associated with key Phase II and Phase III drugs of the company. The analysis will also include an investigation into the mechanism of action as well as preclinical and early clinical data of the agents to conclude on the probability of FDA approval of the drugs.

 

DATA ANALYSIS
Evaluate clinical data associated with key Phase II and Phase III drugs of the company. The analysis will also include an investigation into the mechanism of action as well as preclinical and early clinical data of the agents to conclude on the probability of FDA approval of the drugs.

COMPETITIVE ANALYSIS
Compare clinical trial data of the company's key drugs with that of competitive compounds on market or under development. Solicit key opinion leader views on the competitive parameters and differentiation. Arrive at conclusions on the drugs' approvability and marketability.

 

DATA ANALYSIS
Evaluate clinical data associated with key Phase II and Phase III drugs of the company. The analysis will also include an investigation into the mechanism of action as well as preclinical and early clinical data of the agents to conclude on the probability of FDA approval of the drugs.

COMPETITIVE ANALYSIS
Compare clinical trial data of the company's key drugs with that of competitive compounds on market or under development. Solicit key opinion leader views on the competitive parameters and differentiation. Arrive at conclusions on the drugs' approvability and marketability.

MARKET OPPORTUNITY
Risk adjusted revenue models for key drugs of the company based either on addressable population (underdeveloped markets) or scripts data (developed markets). Penetration rates incorporate data strength, competitive dynamics, reimbursement potential, and key opinion leader views.

 

DATA ANALYSIS
Evaluate clinical data associated with key Phase II and Phase III drugs of the company. The analysis will also include an investigation into the mechanism of action as well as preclinical and early clinical data of the agents to conclude on the probability of FDA approval of the drugs.

COMPETITIVE ANALYSIS
Compare clinical trial data of the company's key drugs with that of competitive compounds on market or under development. Solicit key opinion leader views on the competitive parameters and differentiation. Arrive at conclusions on the drugs' approvability and marketability.

MARKET OPPORTUNITY
Risk adjusted revenue models for key drugs of the company based either on addressable population (underdeveloped markets) or scripts data (developed markets). Penetration rates incorporate data strength, competitive dynamics, reimbursement potential, and key opinion leader views.

INVESTMENT THESIS AND VALUATION
Key reasons why you should be interested or ignore the investment. Consolidated set of earnings model, balance sheet, and cash flow statement. DCF and/or multiple based valuation derived Price Target. Buy, Sell, Hold, or Short Recommendation.